UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.77
+0.32 (2.79%)
Nov 21, 2024, 1:38 PM EST - Market open
UroGen Pharma Revenue
UroGen Pharma had revenue of $25.20M in the quarter ending September 30, 2024, with 20.87% growth. This brings the company's revenue in the last twelve months to $89.36M, up 15.64% year-over-year. In the year 2023, UroGen Pharma had annual revenue of $82.71M with 28.52% growth.
Revenue (ttm)
$89.36M
Revenue Growth
+15.64%
P/S Ratio
4.79
Revenue / Employee
$444,592
Employees
201
Market Cap
496.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Emergent BioSolutions | 1.13B |
Treace Medical Concepts | 202.86M |
Arcturus Therapeutics Holdings | 160.40M |
GRAIL | 117.67M |
Y-mAbs Therapeutics | 84.55M |
REGENXBIO | 84.33M |
Zevra Therapeutics | 24.49M |
OmniAb | 20.41M |
URGN News
- 5 days ago - Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
- 8 days ago - UroGen Pharma: Choice Based On Near Term High Value PDUFA - Seeking Alpha
- 14 days ago - UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - Business Wire
- 16 days ago - UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire
- 22 days ago - UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - Business Wire
- 24 days ago - ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire
- 5 weeks ago - UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - Business Wire